The DOI matches its Crossref record; 143 of the 146 references it cites were found in a registry or an index.
The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors?
Open accessAbstract
The 2016 and 2021 World Health Organization 2021 Classification of central nervous system tumors have resulted in a major improvement in the classification of isocitrate dehydrogenase (IDH)-mutant gliomas. With more effective treatments many patients experience prolonged survival. However, treatment guidelines are often still based on information from historical series comprising both patients with IDH wild-type and IDH-mutant tumors. They provide recommendations for radiotherapy and chemotherapy for so-called high-risk patients, usually based on residual tumor after surgery and age over 40. More up-to-date studies give a better insight into clinical, radiological, and molecular factors associated with the outcome of patients with IDH-mutant glioma. These insights should be used today for risk stratification and for treatment decisions. In many patients with IDH-mutant grades 2 and 3 glioma, if carefully monitored postponing radiotherapy and chemotherapy is safe, and will not jeopardize the overall outcome of patients. With the INDIGO trial showing patient benefit from the IDH inhibitor vorasidenib, there is a sizable population in which it seems reasonable to try this class of agents before recommending radio-chemotherapy with its delayed adverse event profile affecting quality of survival. Ongoing trials should help to further identify the patients that are benefiting from this treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, the grading criteria in the current classification schema for oligodendrogliomas continues to predominantly rely upon histopathologic examination; the differentiating criterion between grade 2 and grade 3 oligodendrogliomas are the presence of conspicuous microvascular proliferation and/or 6 mitoses per 10 high-power field [3,4,5,6,7,8,9,10,11].”
From BPC 157 Therapy of Myotendinous Junction Injury in Rats (2025) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Based on RTOG 9802 and EORTC 22033–26033 criteria, our patient is categorized as high-risk on the basis of his age at diagnosis.”
From BPC 157 Therapy of Myotendinous Junction Injury in Rats (2025) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“On the contrary, he is stratified to a low-risk classification under the EORTC 22844/5 and RTOG 0424 criteria (oligodendroglioma lineage, and absence of pre-operative neurological deficit, unknown preoperative tumor diameter) [10,24,28,32,33,34,35].”
From BPC 157 Therapy of Myotendinous Junction Injury in Rats (2025) · cites this paper as [10]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The role of age as a prognostic indicator for oligodendrogliomas remains a matter of debate with a historical threshold of ≥ 40 years as the benchmark for high-risk classification in grade 2 gliomas [10].”
From BPC 157 Therapy of Myotendinous Junction Injury in Rats (2025) · cites this paper as [10]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
Louis, D. N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee, W. K., Ohgaki, H., Wiestler, O. D., Kleihues, P., & Ellison, D. W. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1545-1 · Cited by 15,657 · cited 1×
“10 15 With the increasing use of early maximal safe surgery and radiotherapy followed by alkylating chemotherapy, the nat-ural history of these tumors can no longer be studied.”
BackgroundSelf-citationThe 2021 WHO classification of tumors of the central nervous system: a summary
Louis, D. N., Perry, A., Wesseling, P., Brat, D. J., Cree, I. A., Figarella-Branger, D., Hawkins, C., Ng, H. K., Pfister, S. M., Reifenberger, G., et al. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab106 · Cited by 12,273 · cited 2×
“68 77 A study based on selected patient cohorts included in EORTC trials 26053 (CATNON) and 22033-26033 reported that ≤ 2 mitoses per 10 microscopic HPF was significantly associated with longer PFS in patients with IDHmt astrocytoma without homozygous CDKN2A/CDKN2B deletion.”
BackgroundSelf-citationDNA methylation-based classification of central nervous system tumours
Capper, D., Jones, D. T. W., Sill, M., Hovestadt, V., Schrimpf, D., Sturm, D., Koelsche, C., Sahm, F., Chavez, L., Reuss, D. E., et al. (2018) · Nature · doi:10.1038/nature26000 · Cited by 3,033 · cited 1×
“135 The prognostic significance of this distinction was confirmed in independent datasets, both in in grade 3 and in grades 2–4 astrocytomas.”
BackgroundSelf-citationCeccarelli, M., Barthel, F. P., Malta, T. M., Sabedot, T. S., Salama, S. R., Murray, B. A., Morozova, O., Newton, Y., Radenbaugh, A., Pagnotta, S. M., et al. (2016) · Cell · doi:10.1016/j.cell.2015.12.028 · Cited by 2,189 · cited 2×
“98 Patients with an initial diagnosis of G-CIMP-low tumors exhibited shorter overall survival compared to those with G-CIMP-high, accompanied by notable alterations in cell cycle pathways, CDKN2A/B deletions, and MET amplifications.”
BackgroundSelf-citationEANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
Weller, M., van den Bent, M., Preusser, M., Le Rhun, E., Tonn, J. C., Minniti, G., Bendszus, M., Balana, C., Chinot, O., Dirven, L., et al. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00447-z · Cited by 2,048
Self-citationZhao, Z., Zhang, K.-N., Wang, Q., Li, G., Zeng, F., Zhang, Y., Wu, F., Chai, R., Wang, Z., Zhang, C., et al. (2021) · Genomics, Proteomics & Bioinformatics · doi:10.1016/j.gpb.2020.10.005 · Cited by 1,098
Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma
Buckner, J. C., Shaw, E. G., Pugh, S. L., Chakravarti, A., Gilbert, M. R., Barger, G. R., Coons, S., Ricci, P., Bullard, D., Brown, P. D., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1500925 · Cited by 1,064 · cited 1×
“2,11,15 Two studies addressed immediate postoperative treatment versus delayed treatment and found no effect on survival; but here also patient selection appears to have played a major role in the choice for early treatment.”
BackgroundPrognostic Factors for Survival in Adult Patients With Cerebral Low-Grade Glioma
Pignatti, F., van den Bent, M., Curran, D., Debruyne, C., Sylvester, R., Therasse, P., Áfra, D., Cornu, P., Bolla, M., Vecht, C., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.121 · Cited by 955
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma
Mellinghoff, I. K., van den Bent, M. J., Blumenthal, D. T., Touat, M., Peters, K. B., Clarke, J., Mendez, J., Yust-Katz, S., Welsh, L., Mason, W. P., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2304194 · Cited by 814
Self-citationTransformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation
Koivunen, P., Lee, S., Duncan, C. G., Lopez, G., Lu, G., Ramkissoon, S., Losman, J. A., Joensuu, P., Bergmann, U., Gross, S., et al. (2012) · Nature · doi:10.1038/nature10898 · Cited by 727 · cited 1×
“141,142 Multiple IDH inhibitors have been developed, some specific for mutant IDH1, while others inhibit both mutant IDH1 and IDH2.”
Background
Research works printed but not linked: 5
- Louis, 2021, The 2021 WHO classification of tumors of the central nervous system: A summary, Neuro-Oncology., 23, 1231, 10.1093/neuonc/noab106 · DOI · Paper page
- Tesileanu, 2021, Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma, Neuro-Oncology., 23, 1547, 10.1093/neuonc/noab088 · DOI
- Appay, 2019, CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas, Neuro Oncol., 21, 1519
- Aoki, 2018, Prognostic relevance of genetic alterations in diffuse lower-grade gliomas, Neuro Oncol., 20, 66, 10.1093/neuonc/nox132 · DOI · Paper page
- Mellinghoff, 2020, Ivosidenib in isocitrate dehydrogenase 1–mutated advanced glioma, J Clin Oncol., 38, 3398, 10.1200/JCO.19.03327 · DOI · Paper page
Cited by
Karschnia, P., Young, J. S., Wijnenga, M. M. J., Sciortino, T., Teske, N., Corell, A., Wagner, A., Youssef, G., Park, Y. W., Häni, L., et al. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(25)00534-0 · Cited by 39
Self-citationThe role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant glioma
de la Fuente, M. I., Touat, M., van den Bent, M. J., Preusser, M., Peters, K. B., Young, R. J., Huang, R. Y., Ellingson, B. M., Capper, D., Phillips, J. J., et al. (2024) · Neuro-Oncology · doi:10.1093/neuonc/noae259 · Cited by 31
Self-citationCanonical amplifications and CDKN2A/B loss refine IDH1/2-mutant astrocytoma prognosis
Ghosh, H. S., Patel, R. V., Claus, E. B., Castro, L. N. G., Wen, P. Y., Ligon, K. L., Meredith, D. M., & Bi, W. L. (2024) · Neuro-Oncology · doi:10.1093/neuonc/noae258 · Cited by 26
“6 As such, classification schemes which more accurately define patient risk remain a critical component in the ongoing effort to develop targeted therapeutics that improve on current standards of care.”
Self-citationvan den Bent, M. J., Ghisai, S. A., Wick, W., Sanson, M., Brandes, A. A., Clement, P., Erridge, S., Vogelbaum, M. A., Nowak, A. K., Baurain, J., et al. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(25)00614-x · Cited by 26
Self-citationGhisai, S. A., van Hijfte, L., Vallentgoed, W., Tesileanu, C. M. S., de Heer, I. J., Kros, J. M., Sanson, M., Gorlia, T., Wick, W., Vogelbaum, M. A., et al. (2024) · Acta Neuropathologica · doi:10.1007/s00401-024-02811-0 · Cited by 22
Self-citation
Metadata
- Authors
- van den Bent, M. J., French, P. J., Brat, D., Tonn, J. C., Touat, M., Ellingson, B. M., Young, R. J., Pallud, J., von Deimling, A., Sahm, F., Figarella Branger, D., Huang, R. Y., Weller, M., Mellinghoff, I. K., Cloughsey, T. F., Huse, J. T., Aldape, K., Reifenberger, G., Youssef, G., Karschnia, P., Noushmehr, H., Peters, K. B., Ducray, F., Preusser, M., & Wen, P. Y.
- Affiliations
- Brain Tumor Center at Erasmus MC Cancer Institute , Rotterdam,
- Erasmus MC Cancer Institute (NL)
- Northwestern University (US)
- Deutsches Konsortium für Translationale Krebsforschung (DE)
- Brigham and Women's Hospital (US)
- University of California, Los Angeles (US)
- Memorial Sloan Kettering Cancer Center (US)
- Inserm (FR)
- Department of Neuropathology, University Hospital Medicine and CCU Neuropathology, German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ) , Heidelberg,
- German Cancer Research Center (DE)
- DFB Aix-Marseille Univ, APHM, CNRS, INP, Inst Neurophysiopathol, CHU Timone, Service d’Anatomie Pathologique et de Neuropathologie , Marseille,
- University of Zurich (CH)
- Department of Neurology, TC David Geffen School of Medicine at UCLA , Los Angeles ,
- The University of Texas MD Anderson Cancer Center (US)
- National Institutes of Health (US)
- Düsseldorf University Hospital (DE)
- Harvard University (US)
- Henry Ford Hospital (US)
- Duke University (US)
- Inserm U1052, CNRS UMR5286, Université Claude Bernard Lyon , Lyon,
- Medical University of Vienna (AT)
- ORCID
- van den Bent, Martin J
- French, Pim J
- Brat, Daniel
- Tonn, Joerg C
- Touat, Mehdi
- Ellingson, Benjamin M
- Young, Robert J
- Pallud, Johan
- von Deimling, Andreas
- Sahm, Felix
- Figarella Branger, Dominique
- Huang, Raymond Y
- Weller, Michael
- Mellinghoff, Ingo K
- Cloughsey, Tim F
- Huse, Jason T
- Aldape, Kenneth
- Reifenberger, Guido
- Youssef, Gilbert
- Karschnia, Philipp
- Noushmehr, Houtan
- Peters, Katherine B
- Ducray, Francois
- Preusser, Matthias
- Wen, Patrick Y
- Venue
- Neuro-Oncology
- Publisher
- Oxford University Press (OUP)
- Published
- 2024-06-24
- Volume
- 26
- Issue
- 10
- Pages
- 1805-1822
- ISSN
- 1522-8517 (ISSN-L)
- 1523-5866
- PMC
- PMC11449017
- OpenAlex
- W4399973103
- Cited by
- 88
- References
- 146
- Citations by year
- 2026: 36 · 2025: 42 · 2024: 10
- FWCI
- 6.66
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Neuro-Oncology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (acceptedVersion, cc-by)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, cc-by-nc-nd)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- HAL AMU (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, cc-by)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Michigan State University
- Institut National de la Santé et de la Recherche Médicale
- Centre National de la Recherche Scientifique
- Hospices Civils de Lyon
- Deutschen Konsortium für Translationale Krebsforschung
- Sorbonne Université
- College of Engineering, Michigan State University
- National Cancer Institute (P30CA008748, P50CA211015, R01CA279984, R01CA270027)
- National Institute of Neurological Disorders and Stroke (R35NS105109)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiomics and Machine Learning in Medical Imaging
- Keywords
- IDH-mutant glioma, isocitrate dehydrogenase inhibitors, vorasidenib, tumor grade, age, tumor enhancement, extent of resection, risk stratification, radiotherapy, chemotherapy, treatment decision-making, overall survival, quality of survival
- MeSH terms
- Clinical Decision-Making, Age Factors, Brain Neoplasms, Enzyme Inhibitors, Glioma, Humans, Isocitrate Dehydrogenase, Mutation, Neoplasm Grading
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors? https://app.cochat.ai/papers/10.1093/neuonc/noae107
- The paper
- van den Bent, M. J., French, P. J., Brat, D., Tonn, J. C., Touat, M., Ellingson, B. M., Young, R. J., Pallud, J., von Deimling, A., Sahm, F., Figarella Branger, D., Huang, R. Y., Weller, M., Mellinghoff, I. K., Cloughsey, T. F., Huse, J. T., Aldape, K., Reifenberger, G., Youssef, G., . . . Wen, P. Y. (2024). The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors? Neuro-Oncology. https://doi.org/10.1093/neuonc/noae107
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
